SUNNYVALE, Calif., July 7, 2011 /PRNewswire/ — Accuray Incorporated
(Nasdaq:
ARAY), the premier radiation oncology company, announced new
clinical data highlighting the ability of its CyberKnife®
Robotic Radiosurgery System and its TomoTherapy®
Radiation Therapy System to treat a wide range of patients with
lung cancer and lung metastases. The new outcome data was presented
at the 14th World Conference on
Lung Cancer, the leading global forum for lung cancer and
thoracic oncology research and practice, which took place July 3-7,
2011 in Amsterdam, The Netherlands.
The CyberKnife System, with its unique tracking and robotic
correcting capabilities, is a dedicated radiosurgery system able to
deliver destructive doses of radiation to tumors throughout the
lung with the highest levels of accuracy, even for tumors close to
critical structures such as the heart and esophagus. The
TomoTherapy system has the ability to deliver both high quality
intensity modulated radiation therapy for larger, complex tumors
and ablative doses of radiation for smaller peripheral lung tumors
that are away from critical structures, making it the premier
hybrid radiation therapy system.
“The data presented this week at the World Conference on Lung
Cancer demonstrate that CyberKnife and TomoTherapy deliver
best-in-class radiation treatment options for a wide range of lung
cancer patients,” said Euan S. Thomson, Ph.D., president and chief
executive officer of Accuray. “The unsurpassed flexibility of these
systems, combined with a growing body of clinical evidence
demonstrating low toxicity and long-term tumor control, make
Accuray’s technologies increasingly critical tools in treatment of
even the
‘/>”/>
